



ASX Announcement

12 April 2017

Attn: Manager of ASX Announcements
Australian Securities Exchange
Level 40 Central Park
152-158 St George's Terrace
Perth WA 6000

NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

Further to the Appendix 3B released to ASX on 12 April 2017, the Directors of Creso Pharma Limited (ASX: CPH) (**Company**) provide a notice for the purposes of section 708A(5)(e) of the Corporations Act 2001.

As part of the Placement announced to ASX on 27th March 2017 to raise over \$8m, a further 4,568,438 fully paid ordinary shares were issued to professional and sophisticated investors at an issue price of A\$0.69 per Share under the Company's 10% Placement Capacity under Listing Rule 7.1A. In addition, 1,250,000 shares were issued in lieu of cash fees for services provided in relation to the Placement.

The Shares are part of a class of securities quoted on ASX and may be subject to a subsequent offer for sale. The Company issued the Shares above without a disclosure document to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (the **Act**).

As at the date of this notice, the Company has complied with:

- a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- b) section 674 of the Act.

As at the date of this notice, there is no excluded information for the purposes of sections 708A(7) and (8) of the Corporations Act.

For and on behalf of the Board

Sarah Smith
(Company Secretary)